Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2013

01.02.2013 | Original Article

Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients

verfasst von: Salih Taşkın, Fırat Ortaç, Korhan Kahraman, Göksu Göç, Derya Öztuna, Mete Güngör

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess clinical, surgical and pathologic variables in survival of advanced endometrial cancer.

Methods

Sixty-seven advanced-stage (stages III and IV according to FIGO 2009) endometrial cancer cases were evaluated retrospectively. The effects on survival of age, histologic subtype, stage, grade, myometrial invasion, optimal cytoreduction, parity and cervical involvement were analyzed.

Results

Cervical involvement (P = 0.033) and nulliparity (P = 0.042) were worsening features in terms of survival. In 56 cases (83.5%) optimal cytoreduction could be achieved and survival was significantly longer in this group than the group who were not optimally cytoreduced (mean 30.4 vs. 9.6 months) (P < 0.01). Depth of myometrial invasion, histologic type of tumor, stage, grade, and age younger or older than 60 years were not found to be related to survival. Neither adjuvant therapy type nor their combination were superior to each other for improving survival.

Conclusions

Cervical stromal involvement is a poor prognostic factor in cases of advanced endometrial carcinoma. Further studies are required to describe the effect of different surgical approaches such as radical hysterectomy on survival in the presence of cervical stromal invasion.
Literatur
1.
Zurück zum Zitat Aalders JG, Abeler V, Kolstad P (1984) Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. Gynecol Oncol 17:64–74PubMedCrossRef Aalders JG, Abeler V, Kolstad P (1984) Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. Gynecol Oncol 17:64–74PubMedCrossRef
2.
Zurück zum Zitat Greven KM, Curran WJ Jr, Whittington R et al (1989) Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 17:35–39PubMedCrossRef Greven KM, Curran WJ Jr, Whittington R et al (1989) Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 17:35–39PubMedCrossRef
3.
Zurück zum Zitat Goff BA, Goodman A, Muntz HG et al (1994) Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 52:237–240PubMedCrossRef Goff BA, Goodman A, Muntz HG et al (1994) Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 52:237–240PubMedCrossRef
4.
Zurück zum Zitat Chi DS, Welshinger M, Venkatraman ES et al (1997) The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 67:56–60PubMedCrossRef Chi DS, Welshinger M, Venkatraman ES et al (1997) The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 67:56–60PubMedCrossRef
5.
Zurück zum Zitat Bristow RE, Zerbe MJ, Rosenshein NB et al (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:85–91PubMedCrossRef Bristow RE, Zerbe MJ, Rosenshein NB et al (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:85–91PubMedCrossRef
6.
Zurück zum Zitat Ayhan A, Taskiran C, Celik C et al (2002) The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer 12:448–453PubMedCrossRef Ayhan A, Taskiran C, Celik C et al (2002) The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int J Gynecol Cancer 12:448–453PubMedCrossRef
7.
Zurück zum Zitat Numazaki R, Miyagi E, Konnai K et al (2009) Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients. Int J Clin Oncol 14:344–350PubMedCrossRef Numazaki R, Miyagi E, Konnai K et al (2009) Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients. Int J Clin Oncol 14:344–350PubMedCrossRef
8.
Zurück zum Zitat van Wijk FH, Huikeshoven FJ, Abdulkadir L et al (2006) Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer 16:1648–1655PubMedCrossRef van Wijk FH, Huikeshoven FJ, Abdulkadir L et al (2006) Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer 16:1648–1655PubMedCrossRef
9.
Zurück zum Zitat Orezzoli JP, Sioletic S, Olawaiye A et al (2009) Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113:316–323PubMedCrossRef Orezzoli JP, Sioletic S, Olawaiye A et al (2009) Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113:316–323PubMedCrossRef
10.
Zurück zum Zitat Barakat RR, Park RC, Grigsby PW et al (1997) Corpus. Epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 2nd edn. Lippincott-Raven, Philadelphia, pp 859–896 Barakat RR, Park RC, Grigsby PW et al (1997) Corpus. Epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 2nd edn. Lippincott-Raven, Philadelphia, pp 859–896
11.
Zurück zum Zitat Fotiou S, Vlahos N, Kondi-Pafiti A et al (2009) Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: role of tumor grade and size. Gynecol Oncol 112:517–520PubMedCrossRef Fotiou S, Vlahos N, Kondi-Pafiti A et al (2009) Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: role of tumor grade and size. Gynecol Oncol 112:517–520PubMedCrossRef
12.
Zurück zum Zitat Lee TS, Kim JW, Kim DY et al (2010) Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci 25:552–556PubMedCrossRef Lee TS, Kim JW, Kim DY et al (2010) Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci 25:552–556PubMedCrossRef
13.
Zurück zum Zitat Albrektsen G, Heuch I, Wik E et al (2009) Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer 19:665–669PubMedCrossRef Albrektsen G, Heuch I, Wik E et al (2009) Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer 19:665–669PubMedCrossRef
14.
Zurück zum Zitat Behbakht K, Yordan EL, Casey C et al (1994) Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 55:363–367PubMedCrossRef Behbakht K, Yordan EL, Casey C et al (1994) Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 55:363–367PubMedCrossRef
15.
Zurück zum Zitat Pliskow S, Penalver M, Averette HE (1990) Stage III and stage IV endometrial carcinoma: a review of 41 cases. Gynecol Oncol 38:210–215PubMedCrossRef Pliskow S, Penalver M, Averette HE (1990) Stage III and stage IV endometrial carcinoma: a review of 41 cases. Gynecol Oncol 38:210–215PubMedCrossRef
16.
Zurück zum Zitat Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44PubMedCrossRef Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36–44PubMedCrossRef
17.
Zurück zum Zitat Maggi R, Lissoni A, Spina F et al (2006) Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 95:266–271PubMedCrossRef Maggi R, Lissoni A, Spina F et al (2006) Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 95:266–271PubMedCrossRef
Metadaten
Titel
Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients
verfasst von
Salih Taşkın
Fırat Ortaç
Korhan Kahraman
Göksu Göç
Derya Öztuna
Mete Güngör
Publikationsdatum
01.02.2013
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0351-y

Weitere Artikel der Ausgabe 1/2013

International Journal of Clinical Oncology 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.